AG
DNLI icon

AIA Group’s Denali Therapeutics DNLI Stock Holding History

AIA Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,815
Closed -$2.18M – 305
2024
Q3 		$2.18M Buy
74,815
+5,471
+8% +$136K 0.06% 150
2024
Q2 		$1.61M Buy
69,344
+8,310
+14% +$160K 0.05% 178
2024
Q1 		$1.25M Sell
61,034
-7,044
-10% -$132K 0.04% 189
2023
Q4 		$1.46M Sell
68,078
-369
-0.5% -$7.31K 0.06% 152
2023
Q3 		$1.41M Buy
68,447
+12,203
+22% +$310K 0.07% 133
2023
Q2 		$1.66M Buy
56,244
+5,980
+12% +$168K 0.08% 122
2023
Q1 		$1.16M Buy
50,264
+27,502
+121% +$757K 0.06% 136
2022
Q4 		$633K Sell
22,762
-14,264
-39% -$424K 0.04% 200
2022
Q3 		$1.14M Sell
37,026
-38
-0.1% -$1.24K 0.07% 111
2022
Q2 		$1.09M Sell
37,064
-4,321
-10% -$113K 0.06% 146
2022
Q1 		$1.33M Sell
41,385
-66,457
-62% -$2.29M 0.06% 145
2021
Q4 		$4.81M Buy
107,842
+9,401
+10% +$445K 0.23% 59
2021
Q3 		$4.97M Buy
98,441
+16,550
+20% +$933K 0.28% 59
2021
Q2 		$5.3M Buy
81,891
+27,516
+51% +$1.7M 0.36% 50
2021
Q1 		$3.1M Buy
54,375
+17,937
+49% +$1.2M 0.45% 53
2020
Q4 		$2.49M Buy
+36,438
New +$2.2M 0.29% 53

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AIA Group's DNLI Position: Q4 2024 in Review

AIA Group sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 74,815 shares — an estimated $2.18M sold.

AIA Group first reported a position in DNLI in Q4 2020 and held it in 16 quarters. The position peaked at $5.3M in Q2 2021. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • AIA Group reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AIA Group sold 74,815 Denali Therapeutics shares in Q4 2024, an estimated $2.18M.
  • AIA Group first reported a position in Denali Therapeutics in Q4 2020 and held it in 16 quarters.
  • AIA Group's Denali Therapeutics position peaked at $5.3M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on AIA Group's 13F filing for Q4 2024, filed 12 Feb 2025.